Kite Pharma (KITE) Adopts BioLife Solutions’ (BLFS) CryoStor In Production Process; Upside Visualized In Devon Energy (DVN)


Shares of BioLife Solutions, Inc. (Nasdaq:BLFS) soared more than 80% in pre-market trade Monday after the company said that it has reached a 10-year supply deal for its CryoStor clinical grade freeze media with Kite Pharma, Inc. (Nasdaq:KITE)

According to BioLife Solutions, the clinical-stage biopharmaceutical company has adopted CryoStor in its manufacturing process for CAR T cell therapy KTE-C19

BLFS stock closed at $1.53, down $0.10 (or -6.13%) on Friday.

BioLife Solutions, which develops, manufactures, and markets patented hypothermic storage and cryopreservation solutions for cells and tissues, has 12.45M Shares Outstanding and BLFS stock 52-week range is from $1.51 to $4.44 per share. . At close on Friday, the company had a Market Capitalization of $19.42M



Investment analysts at Scotia Howard Weil upgraded shares of Devon Energy Corp. (NYSE:DVN) from a Sector Outperform to a Focus Stock rating and boosted their price target from $50.00 to $61.00, sending the stock up about 1.6% before the opening bell Monday

DVN stock finished at $37.58, up $0.77 (or +2.09%) on Friday’s trading session

Devon Energy, which engaged in the exploration, development and production of oil, natural gas and natural gas liquids, has 524.00M Shares Outstanding, Market Capitalization (intraday) of $19.69B and DVN stock one-year range is between $18.07 and $67.96 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at